Around **1 billion people** worldwide have obstructive sleep apnea (OSA) — a condition in which the muscles at the back of the throat relax during sleep, partially blocking the airway and causing breathing to repeatedly stop and start throughout the night.
For decades, the only effective treatment was a device called CPAP (Continuous Positive Airway Pressure): a mask worn while sleeping that pumps a constant stream of pressurised air to keep the airway open. It works. Many patients find it life-changing. But somewhere between 30% and 50% of people prescribed CPAP **cannot tolerate wearing it**. They feel claustrophobic. The noise keeps them awake. The mask is uncomfortable. They abandon it.
For these patients — hundreds of millions of people — there has been no good pharmacological alternative. Until now.
**The Lancet Trial**
A Phase 2 clinical trial, involving **240 to 298 patients** with moderate to severe obstructive sleep apnea across multiple European countries, has tested a drug called **sulthiame** — an existing anti-seizure medication already approved for childhood epilepsy in several European nations, Israel, Japan, and Australia.
The results, published in **The Lancet in March 2026**, are the most promising ever reported for a sleep apnea medication:
🌙 **Up to 50% reduction in breathing interruptions** (at higher doses, measured by AHI4 — the strict criterion counting only severe oxygen drops) 🌙 **34.8% reduction** in breathing pauses at 200mg dose (AHI3a measure) 🌙 **39.9% reduction** at 300mg dose 🌙 **Significant improvements in overnight oxygen saturation** — the body getting more oxygen throughout the night 🌙 **Generally well-tolerated** — most side effects were mild, temporary, and dose-dependent
The most commonly reported side effect was paresthesia — a tingling sensation — which increased with dose but was typically mild and transient.
**How It Works**
Sulthiame is a **carbonic anhydrase inhibitor** — a class of compounds that play a role in regulating the body's breathing drive.
Normally, the brain monitors CO₂ levels in the blood and adjusts breathing rate accordingly. In obstructive sleep apnea, this system becomes unstable during sleep: the breathing drive wavers, the airway collapses, and the cycle of obstruction begins.
Sulthiame appears to **stabilise and strengthen the brain's respiratory drive** — making the system that controls breathing more consistent during sleep, reducing the likelihood that the airway will collapse. Rather than holding the airway open mechanically (as CPAP does), it works upstream, at the level of the neural signals that control breathing in the first place.
For patients with high "loop gain" — an unstable breathing control response — this mechanism is particularly well-suited.
**Why This Matters So Much**
Sleep apnea isn't a nuisance. Untreated, it's a serious health risk:
❤️ **Cardiovascular disease** — Chronic oxygen deprivation during sleep raises blood pressure, increases the risk of heart attack and stroke, and stresses the heart 🧠 **Cognitive decline** — Disrupted sleep and low oxygen accelerate memory loss and increase dementia risk ⚡ **Fatigue and accidents** — OSA is a major cause of drowsy driving and workplace accidents 💊 **Mental health** — Disrupted deep sleep is linked to anxiety and depression
The patients who might benefit most from sulthiame are exactly those who need it most: the hundreds of millions who have tried CPAP, found it intolerable, and returned to interrupted, oxygen-depleted nights.
**What Comes Next**
This was a Phase 2 trial. Phase 3 trials — larger, longer, in more diverse patient populations — are required before regulatory approval. But the size of the effect, the clear dose-response relationship, and the publication in *The Lancet* (one of medicine's most rigorous journals) signal that this is a genuinely serious candidate.
Researchers at the University of Gothenburg, who led part of the work, have called a first pharmacological treatment for sleep apnea "within reach."
For 1 billion people who stop breathing in the night — for the hundreds of millions who cannot tolerate the only proven treatment — "within reach" is the best news they've heard in decades. 💊😴
*Sources: The Lancet (Phase 2 clinical trial, March 2026) · ScienceDaily (March 11, 2026) · Science Alert · Gizmodo · University of Gothenburg · Apnimed · AJMC*
